Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiromichi Nishimura is active.

Publication


Featured researches published by Hiromichi Nishimura.


Journal of Acquired Immune Deficiency Syndromes | 1996

An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support.

Hirokuni Taguchi; Kenichiro Kinoshita; Kiyoshi Takatsuki; Masao Tomonaga; Koichi Araki; Naomichi Arima; Shu-ichi Ikeda; Koji Uozumi; Hidehisa Kohno; Fumio Kawano; Hiroshi Kikuchi; Hironori Takahashi; Kazuo Tamura; Shin Chiyoda; Hiroyuki Tsuda; Hiromichi Nishimura; Takafumi Hosokawa; Hiromitsu Matsuzaki; Saburo Momita; Osamu Yamada; Isao Miyoshi

SUMMARY An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in adult T-cell leukemia/lymphoma (ATLL) patients in a multiinstitutional, cooperative study. Vincristine 1 mg/m2 i.v. day 1, Adriamycin 40 mg/m2 i.v. day 1, cyclophosphamide 400 mg/m2 i.v. day 1, prednisolone 40 mg/m2 i.v. days 1 to 3 and 8 to 10, etoposide 35 mg/m2 i.v. days 1 to 8, vindesine 2 mg/m2 i.v. day 8, ranimustine 50 mg/m2 i.v. day 8, mitoxantrone 7 mg/m2 i.v. day 8, and G-CSF 50 mg/m2 s.c. days 9 to 21 were given for 2 to 4 courses every 3 weeks to 83 patients with ATLL. Complete remission (CR) and partial remission (PR) were achieved in 35.8 and 38.3 percent, respectively, of 81 evaluable patients. The median survival of all patients was 8.5 months, with a predicted 3-year survival of 13.5 percent by the Kaplan-Meier method. The median duration of response was 7.6 months (range 0.2-42.7), and 13 patients were alive. Their median survival time was 29.1 months (range 19.2-44.7). In 67.6 percent of courses, white blood cell (WBC) nadirs were < 1.0 x 10(9)/L. Days required for the recovery of WBC from the nadir to > 1.0 x 10(9)/L were <5 days in 71.4 percent of the treatment courses. The G-CSF supported an intensified chemotherapy regimen for ATLL and yielded better response rate and longer survival compared to previous reports in Japan. Because duration of remission is still short, further studies of postremission therapy or other strategies are warranted.


Cancer | 1985

Familial adult T-cell leukemia.

Yuichi Miyamoto; Kazunari Yamaguchi; Hiromichi Nishimura; Kiyoshi Takatsuki; Tadashi Motoori; Minoru Morimatsu; Tatsuomi Yasaka; Ippei Ohya; Teruto Koga

Two siblings who developed adult T‐cell leukemia (ATL) are presented. The patient and 7 of 26 healthy family members examined had the serum antibodies against ATL‐associated antigens (ATLA). This family study shows that two main routes of transmission of human T‐cell leukemia virus (HTLV) may be involved: one is the route from parents to children and the other is horizontal transmission among spouses, especially from husband to wife; the anti‐ATLA‐positive family is considered to be a high‐risk group for ATL.


Blood | 1983

A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases

Kazunari Yamaguchi; Hiromichi Nishimura; H Kohrogi; M Jono; Y Miyamoto; Kiyoshi Takatsuki


Blood | 1984

The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy

Kazunari Yamaguchi; Motoharu Seiki; Minoru Yoshida; Hiromichi Nishimura; Fumio Kawano; Kiyoshi Takatsuki


Cancer Research | 1985

Clinical Diversity in Adult T-Cell Leukemia-Lymphoma

Kiyoshi Takatsuki; Kazunari Yamaguchi; Fumio Kawano; Toshio Hattori; Hiromichi Nishimura; Hiroyuki Tsuda; Isao Sanada; Kiyonobu Nakada; Yayeko Itai


Blood | 1985

Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity

Isao Sanada; R Tanaka; E Kumagai; Hiroyuki Tsuda; Hiromichi Nishimura; Kazunari Yamaguchi; Fumio Kawano; H Fujiwara; Kiyoshi Takatsuki


Cancer Research | 1989

Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.

Tetsuyuki Kiyokawa; K. Shirono; Toshio Hattori; Hiromichi Nishimura; Kazunari Yamaguchi; J. C. Nichols; T. B. Strom; John R. Murphy; Kiyoshi Takatsuki


Blood | 1989

Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia

Kenji Shirono; Toshio Hattori; Hiroyuki Hata; Hiromichi Nishimura; Kiyoshi Takatsuki


Cancer | 1984

Unusual clinical courses of adult T-cell leukemia in siblings.

Fumio Kawano; Hiroyukl Tsuda; Kazunari Yamaguchi; Hiromichi Nishimura; Isao Sanada; Hiromitsu Matsuzaki; Masao Ishii; Kiyoshi Takatsuki


Japanese Journal of Clinical Oncology | 1984

Blast Crisis of Chronic Myelogenous Leukemia with Tumor Formation Characterized by T-cell Features—A Case Report

Chisa Taniguchi; Kazunari Yamaguchi; Ritsuko Yoshioka; Nobuhide Takifuji; Kaoru Matsui; Hiromichi Nishimura; Shinhachiro Tomino; Kiyoshi Takatsuki; Ryuji Tanaka

Collaboration


Dive into the Hiromichi Nishimura's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge